MEK1/2 inhibitors in the treatment of gynecologic malignancies

Gynecologic Oncology

Volumn 133, Issue 1, 2014, Pages 128-137

  Miller, Caela R ^a   Oliver, Kate E ^b   Farley, John H ^c  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Low grade; MAPK cascade; MEK inhibitors; Ovarian; Serous

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO) N (2 HYDROXYETHOXY) 5 [(3 OXO 1,2 OXAZINAN 2 YL)METHYL]BENZAMIDE; ARRY 300; ARRY 438162; ARRY 704; AZD 8330; B RAF KINASE; BAY 869766; COBIMETINIB; DOXORUBICIN; GOG 281; GSK 2141795; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MSC 2015103B; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PACLITAXEL; PD 0325901D; PIMASERTIB; RAF PROTEIN; RAS PROTEIN; RDEA 119; REFAMETINIB; RG 7421; RO 49879655; RO 5126766; SELUMETINIB; TAK 733; TOPOTECAN; TRAMETINIB; UNCLASSIFIED DRUG; WX 554; XL 518D;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COLLOID CARCINOMA; COLON CANCER; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE MUTATION; GYNECOLOGIC CANCER; HUMAN; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTATIC MELANOMA; MULTICENTER STUDY (TOPIC); MYELOMA; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SOLID TUMOR; THYROID PAPILLARY CARCINOMA; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX CANCER;

CANCER; LOW GRADE; MAPK CASCADE; MEK INHIBITORS; OVARIAN; SEROUS;

CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE SIGNALING SYSTEM; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84897415324     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.01.008     Document Type: Review

References (61)

1. L. Chang, and M. Karin Mammalian MAP kinase signalling cascades Nature 410 6824 Mar 1 2001 37 40
2. M. Takekawa, K. Tatebayashi, and H. Saito Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases Mol Cell 18 3 Apr 29 2005 295 306
3. A. Akinleye, M. Furqan, N. Mukhi, P. Ravella, and D. Liu MEK and the inhibitors: from bench to bedside J Hematol Oncol 6 Apr 12 2013 27
4. T.O. Fischmann, C.K. Smith, T.W. Mayhood, J.E. Myers, P. Reichert, and A. Mannarino et al. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors Biochemistry 48 12 Mar 31 2009 2661 2674
5. Y. Cheng, G. Zhang, and G. Li Targeting MAPK pathway in melanoma therapy Cancer Metastasis Rev 32 3-4 Dec 2013 567 584
6. B.B. Friday, and A.A. Adjei Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy Clin Cancer Res 14 2 Jan 15 2008 342 346
7. M. Kohno, S. Tanimura, and K. Ozaki Targeting the extracellular signal-regulated kinase pathway in cancer therapy Biol Pharm Bull 34 12 2011 1781 1784
8. P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, and V.M. Good et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 6 Mar 19 2004 855 867
9. J.A. McCubrey, L.S. Steelman, W.H. Chappell, S.L. Abrams, R.A. Franklin, and G. Montalto et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance Oncotarget 3 10 Oct 2012 1068 1111
10. C.Y. Hsu, R. Bristow, M.S. Cha, B.G. Wang, and R.J. HO CL Kurman et al. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas Clin Cancer Res 10 19 Oct 1 2004 6432 6436
11. D.B. Solit, L.A. Garraway, C.A. Pratilas, A. Sawai, G. Getz, and A. Basso et al. BRAF mutation predicts sensitivity to MEK inhibition Nature 439 7074 Jan 19 2006 358 362
12. I. Diaz-Padilla, A.L. Malpica, L. Minig, L.M. Chiva, D.M. Gershenson, and A. Gonzalez-Martin Ovarian low-grade serous carcinoma: a comprehensive update Gynecol Oncol 126 2 Aug 2012 279 285
13. L.A. Fecher, S.D. Cummings, M.J. Keefe, and R.M. Alani Toward a molecular classification of melanoma J Clin Oncol 25 12 Apr 20 2007 1606 1620
14. B.R. Davies, A. Logie, J.S. McKay, P. Martin, S. Steele, and R. Jenkins et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models Mol Cancer Ther 6 8 Aug 2007 2209 2219
15. G. Pohl, C.L. Ho, R.J. Kurman, R. Bristow, T.L. Wang, and Ie M. Shih Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations Cancer Res 65 5 Mar 1 2005 1994 2000
16. N. Nakayama, K. Nakayama, S. Yeasmin, M. Ishibashi, A. Katagiri, and K. Iida et al. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer Br J Cancer 99 12 Dec 16 2008 2020 2028
17. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Kdkins, and S. Clegg et al. Mutations of the BRAF gene in human cancer Nature 417 6892 Jun 27 2002 949 954
18. A.A. Adjei, R.B. Cohen, W. Franklin, C. Morris, D. Wilson, and J.R. Molina et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers J Clin Oncol 26 13 May 1 2008 2139 2146
19. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 1 Jan 2013 11 30
20. C.L. Kosary Chapter 16. Cancer of the ovary L.A.G. Ries, J.L. Young, G.E. Keel, M.P. Eisner, Y.D. Lin, M.J. Horner, SEER survival monograph: cancer survival among adults: U.S. SEER program, 1988-2001, Patient and tumor characteristics. Vol NIH Pub. No. 07-6215 2007 National Cancer Institute, SEER Program Bethesda, MD 133 144
21. NCCN guidelines version 2.2013: epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer 2012 National Comprehensive Cancer Network, Inc. [Available at: http://www.nccn.org/professionals/physician-gls/pdf/ovarian. pdf. Accessed August 1, 2013]
22. D.M. Gershenson The life and times of low-grade serous carcinoma of the ovary American Society of Clinical Oncology educational book/ASCO American Society of Clinical Oncology meeting. 2013 2013 195 199
23. G. Singer, R. Stöhr, L. Cope, R. Dehari, A. Hartmann, and D.F. Cao et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation Am J Surg Pathol 29 2 Feb 2005 218 224
24. T. May, C. Virtanen, M. Sharma, A. Milea, H. Begley, and B. Rosen et al. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary Gynecol Oncol 117 1 Apr 2010 9 17
25. D.M. Gershenson, C.C. Sun, D. Bodurka, R.L. Coleman, K.H. Lu, and A.K. Sood et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant Gynecol Oncol 114 1 Jul 2009 48 52
26. J. Farley, W.E. Brady, V. Vathipadiekal, H.A. Lankes, R. Coleman, and M.A. Morgan et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study Lancet Oncol 14 2 Feb 2013 134 140
27. A.N. Fader, J. Java, T.C. Krivak, R.E. Bristow, A.I. Tergas, and M.A. Bookman et al. The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study Gynecol Oncol Dec 13 2013 10.1016/j.ygyno.2013.11.016 [epub.]
28. G. Singer, R. Oldt III, Y. Cohen, B.G. Wang, D. Sidransky, and R.J. Kurman et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 6 Mar 19 2003 484 486
29. K.K. Wong, Y.T. Tsang, M.T. Deavers, S.C. Mok, Z. Zu, and C. Sun et al. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas Am J Pathol 177 4 Oct 2010 1611 1617
30. K.T. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, and M. Milhem et al. Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 2 Jul 12 2012 107 114
31. BRAF and MEK inhibitors approved for melanoma Cancer Discov 3 8 Aug 2013 OF6
32. E. Jokinen, N. Laurila, and J.P. Koivunen Alternative dosing of dual PI3K and MEK inhibition in cancer therapy BMC Cancer 12 Dec 21 2012 612
33. T. Yamaguchi, R. Kakefuda, N. Tajima, Y. Sowa, and T. Sakai Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo Int J Oncol 39 1 Jul 2011 23 31
34. J.R. Infante, L.A. Fecher, G.S. Falchook, S. Nallapareddy, M.S. Gordon, and C. Becerra et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial Lancet Oncol 13 8 Aug 2012 773 781
35. P.A. Janne, A.T. Shaw, J.R. Pereira, G. Jeannin, J. Vansteenkiste, and C. Barrios et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study Lancet Oncol 14 1 Jan 2013 38 47
36. J. Yoon, K.H. Koo, and K.Y. Choi MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy Cancer Res 71 2 Jan 15 2011 445 453
37. E. Martinelli, T. Troiani, E. D'Aiuto, F. Morgillo, D. Vitagliano, and A. Capasso et al. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells Int J Cancer 133 9 Nov 2013 2089 2101
38. C. Iverson, G. Larson, C. Lai, L.T. Yeh, C. Dadson, and P. Weingarten et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer Cancer Res 69 17 Sep 1 2009 6839 6847
39. Q. Chang, M.S. Chapman, J.N. Miner, and D.W. Hedley Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts BMC Cancer 10 Sep 28 2010 515
40. L. Gore, K. Lewis, D.D. Von Hoff, G.J. Weiss, R.K. Ramanathan, and A.A. Adjei et al. Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer. 2011 ASCO annual meeting, Chicago, IL, June 2011 J Clin Oncol 29 15 Suppl. 1 May 20 2011 [abstr 3007]
41. S.D. Barrett, A.J. Bridges, D.T. Dudley, A.R. Saltiel, J.H. Fergus, and C.M. Flamme et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901 Bioorg Med Chem Lett 18 24 Dec 15 2008 6501 6504
42. Y.C. Henderson, Y. Chen, M.J. Frederick, S.Y. Lai, and G.L. Clayman MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo Mol Cancer Ther 9 7 Jul 2010 1968 1976
43. E.B. Haura, A.D. Ricart, T.G. Larson, B.J. Stella, L. Bazhenova, and V.A. Miller et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer Clin Cancer Res 16 8 Apr 15 2010 2450 2457
44. P.A. Ascierto, D. Schadendorf, C. Berking, S.S. Agarwala, C.M. van Herpen, and P. Queirolo et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study Lancet Oncol 14 3 Mar 2013 249 256
45. E. von Euw, M. Atefi, N. Attar, C. Chu, S. Zachariah, and B.L. Burgess et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines Mol Cancer 11 Apr 19 2012 22
46. M. Martinez-Garcia, U. Banerji, J. Albanell, R. Bahleda, S. Dolly, and F. Kraeber-Bodere et al. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors Clin Cancer Res 18 17 Sep 1 2012 4806 4819
47. K. Honda, N. Yamamoto, H. Nokihara, Y. Tamura, H. Asahina, and Y. Yamada et al. Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors Cancer Chemother Pharmacol 72 3 Sep 2013 577 584
48. Y. Isshiki, Y. Kohchi, H. Iikura, Y. Matsubara, K. Asoh, and T. Murata et al. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent Bioorg Med Chem Lett 21 6 Mar 15 2011 1795 1801
49. S. Leijen, M.R. Middleton, P. Tresca, F. Kraeber-Bodere, V. Dieras, and M.E. Scheulen et al. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors Clin Cancer Res 18 17 Sep 1 2012 4794 4805
50. H. Wong, L. Vernillet, A. Peterson, J.A. Ware, L. Lee, and J.F. Martini et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor Clin Cancer Res 18 11 Jun 1 2012 3090 3099
51. E.M. Wallace, J. Lyssikatos, J.F. Blake, A. Marlow, J. Greschuk, and T. Yeh et al. AZD8330 (ARRY-424704): preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trials 100th annual meeting of the American Association for Cancer Research April 2009 [Denver, CO. Abstr 3696]
52. R.B. Cohen, S. Aamdal, M. Nyakas, M. Cavllin, D. Green, and M. Learoyd et al. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies Eur J Cancer 49 7 May 2013 1521 1529
53. J.S. Sebolt-Leopold, D.T. Dudley, R. Herrera, K. Van Becelaere, A. Wiland, and R.C. Gowan et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo Nat Med 5 7 Jul 1999 810 816
54. M.T. Rahman, K. Nakayama, M. Rahman, H. Katagiri, A. Katagiri, and T. Ishibashi et al. KRAS and MAPK1 gene amplification in type II ovarian carcinomas Int J Mol Sci 14 7 Jul 2 2013 13748 13762
55. B. Weigelt, P.H. Warne, M.B. Lambros, J.S. Reis-Filho, and J. Downward PI3K pathway dependencies in endometrioid endometrial cancer cell lines Clin Cancer Res 19 13 Jul 1 2013 3533 3544
56. M.L. Sos, S. Fischer, R. Ullrich, M. Peifer, J.M. Heuckmann, and M. Koker et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer Proc Natl Acad Sci U S A 106 2009 18351 18356
57. K. Oda, K. Shoji, S. Nakagawa, T. Kashiyama, Y. Ikeda, and Y. Miyamoto et al. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas [abstract] J Clin Oncol 29 2011 [abstract nr 5110]
58. F. Marampon, G.L. Gravina, V.M. Popov, L. Scarsella, C. Festuccia, and M.E. La Verghetta et al. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecologic cancer cell lines Int J Oncol 44 1 Jan 2014 285 294
59. J.Y. Hou, A. Rodriguez-Gabin, L. Samaweera, R. Hazan, G.L. Goldberg, and S.B. Horwitz et al. Exploiting MEK inhibitor-mediated activation of ERalpha for therapeutic intervention in ER-positive ovarian carcinoma PLoS One 8 2 2013 e54103
60. M. Nonaka, H. Itamochi, W. Kawaguchi, A. Kudoh, S. Sato, and K. Uegaki et al. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells Int J Gynecol Cancer 22 6 Jul 2012 922 929
61. K.M. Kinross, K.G. Montgomery, M. Kleinschmidt, P. Waring, I. Ivetac, and A. Tikoo et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice J Clin Invest 122 2 Feb 1 2012 553 557